Skip to main content
πŸ«„GASTROENTEROLOGY

Inflammatory Bowel Disease

Crohn's, ulcerative colitis, celiac β€” from symptom suppression to microbiome repair and mucosal healing

~7 million people worldwide with IBD; ~1 in 100 with celiac disease; hundreds of millions with functional GI disorders
IN HUMAN TRIALS
45/ 100
TO BROAD CURE

MILESTONEOral IL-23 inhibitors and advanced small molecules are broadening remission options for IBD.

LATESTNew oral selective IL-23 and TL1A agents entered pivotal trials.

Disease-modifying therapies are in human clinical trials Β· Not medical advice.

CURRENT STATUS

A wave of targeted biologics and oral small molecules (anti-IL-23s like risankizumab and mirikizumab, JAK/S1P modulators) now drives many patients to endoscopic remission β€” not just symptom control. Intestinal microbiota transplant is being standardized, and nanoparticle gene delivery plus celiac-specific tolerance therapies are entering trials.

KEY BREAKTHROUGHS

Risankizumab (Skyrizi) & mirikizumab (Omvoh) β€” IL-23 inhibitors driving endoscopic remission in Crohn's and ulcerative colitis

TL1A antibodies (e.g., tulisokibart) β€” first-in-class pathway showing strong Phase 2 IBD results with a predictive genetic biomarker

Intestinal Microbiota Transplant (IMT) protocols being standardized for ulcerative colitis and recurrent C. difficile

AI endoscopic scoring systems now grade mucosal healing at expert level, standardizing trial endpoints

AI-COMPRESSED PIPELINE

AI TOOLS ACCELERATING CURES

Microbiome Sequencing AIEndoscopic Deep-Learning ScoringMulti-omics Response PredictionNanoparticle Gene Delivery Design

KEY ORGANIZATIONS

AbbVieEli LillyTakedaJohnson & JohnsonSeres / Microbiome consortia

KEY CLINICAL TRIALS

TL1A Antibody (Tulisokibart / PRA023) in Ulcerative Colitis & Crohn's

View

Merck (Prometheus Biosciences)

A first-in-class anti-TL1A antibody paired with a companion genetic test that predicts responders. Targets a newly validated inflammatory pathway with the goal of deeper, more durable remission than existing biologics.

πŸ‘₯ Phase 2/3 programs across UC and Crohn's diseaseπŸ“ US, EU β€” multicenter

Intestinal Microbiota Transplant for Ulcerative Colitis

View

Academic microbiome consortia (multi-site)

Standardized donor-derived microbiota transplant, sometimes paired with diet conditioning, aiming to reset a dysbiotic gut microbiome and induce remission in ulcerative colitis without immunosuppression.

πŸ‘₯ Recruiting β€” randomized vs. placebo/standard careπŸ“ US, Australia, EU β€” academic centers

TIMELINE ESTIMATE

IBD deep remission (biologics/small molecules): available now for many; broad microbiome-based cures 3–6 years. Celiac tolerance therapy: 4–8 years.

EXPLORE FULL CURE PROTOCOL